InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | 2026-05-01 | Wassil Jim | CHIEF OPERATING OFFICER | Sale | 2,250 | $56.83 | $128K | 160.7K | View ↗ | |
| 2026-04-01 | 2026-04-03 | Wassil Jim | CHIEF OPERATING OFFICER | Sale | 2,250 | $58.43 | $131K | 163.0K | View ↗ | |
| 2026-03-10 | 2026-03-11 | Wassil Jim | CHIEF OPERATING OFFICER | Sale | 7,395 | $58.88 | $435K | 166.8K | View ↗ |
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-04-28 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-04-15 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-04-14 | Gilbert Cisneros(D-CA31) | house | Purchase | $1,001 - $15,000 |
| 2025-03-05 | Jefferson Shreve(R-IN06) | house | Sale | $15,001 - $50,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $794.3M+66.6% | $476.6M+43.4% | $332.3M+96.1% | $169.5M |
| Acquired manufacturing rights | $0 | $0-100.0% | $75.0M | — |
| General and administrative | $129.4M+39.3% | $92.9M+53.1% | $60.7M+52.5% | $39.8M |
| Total operating expenses | $923.7M+62.2% | $569.5M+21.7% | $468.0M+101.5% | $232.3M |
| Loss from operations | -$923.7M-62.2% | -$569.5M-21.7% | -$468.0M-101.5% | -$232.3M |
| Interest income | $119.7M+8.8% | $110.0M+74.9% | $62.9M+652.8% | $8.4M |
| Other income (expense) | $37.3M+953.2% | -$4.4M-252.5% | $2.9M+587.8% | $417K |
| Total other income, net | $157.0M+48.7% | $105.6M+60.6% | $65.8M+649.9% | $8.8M |
| Net loss | -$766.6M-65.2% | -$463.9M-15.3% | -$402.3M-80.0% | -$223.5M |
| Net loss per share, basic (in dollars per share) | -$6K-48.2% | -$4K+8.2% | -$4K-20.3% | -$3K |
| Net loss per share, diluted (in dollars per share) | -$6K-48.2% | -$4K+8.2% | -$4K-20.3% | -$3K |
| Weighted-average shares outstanding, basic (in shares) | $136.09B+11.6% | $122.00B+25.6% | $97.16B+49.8% | $64.88B |
| Weighted-average shares outstanding, diluted (in shares) | $136.09B+11.6% | $122.00B+25.6% | $97.16B+49.8% | $64.88B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial Stage
Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference